natgillin/translations-raw huggingface dataset:
Dosisændring på grund af toksicitet, når capecitabin anvendes kontinuerligt i kombination med andre lægemidler, skal foretages efter tabel 3 ovenfor for capecitabin og efter det pågældende produktresumé for det andet lægemiddel/de andre lægemidler.
Dose modifications for toxicity when capecitabine is used continuously in combination with other medicinal products should be made according to table 3 above for capecitabine and according to the appropriate summary of product characteristics for the other medicinal product(s).
60 filmovertrukne tabletter
60 film-coated tablets
Feber,
+Fever,
Capecitabin var mindst ækvivalent med 5-FU/LV intravenøs mht. sygdomsfri overlevelse i protokolpopulationen (hazard ratio 0,92; 95 % konfidensinterval 0,80-1,06).
Capecitabine was at least equivalent to intravenous 5-FU/LV in disease-free survival in per protocol population (hazard ratio 0.92; 95% CI 0.80-1.06).
Analysen for det sekundære endepunkt, relapsfri overlevelse, støtter dissse resultater med en hazard ratio på 0,78 (95 % konfidensinterval = [0,67; 0,92], p = 0,0024) for XELOX versus 5-FU/LV.
The analysis for the secondary endpoint of RFS supports these results with a HR of 0.78 (95% CI=[0.67; 0.92]; p=0.0024) for XELOX vs. 5-FU/LV.
Interferon-alfa Capecitabins MTD var 2.000 mg/m 2/dag, når det kombineredes med interferon alfa-2a (3 MIE/m 2/dag)
Interferon alpha: the MTD of capecitabine was 2000 mg/m2 per day when combined with interferon alpha-2a (3 MIU/m2 per day) compared to 3000 mg/m2 per day when capecitabine was used alone.
ved 2. forekomst ved 3. forekomst ved 4. forekomst
-2nd appearance -3rd appearance -4th appearance
Hæmaturi, Proteinuri, Nedsat renal kreatininclearance, Dysuri
Haematuria, Proteinuria, Creatinine renal clearance decreased, Dysuria
Efter behandling med capecitabin er der set hudtoksicitet, karakteriseret ved degenerative/regressive forandringer.
Skin toxicity, characterised by degenerative/regressive changes, was observed with capecitabine.
I dette studie randomiseredes 255 patienter til behandling med capecitabin (1.250 mg/m2 to gange dagligt i 2
In this trial, 255 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Ecansya 150 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 150 mg capecitabin.
QUALITATIVE AND QUANTITATIVE COMPOSITION Ecansya 150 mg film-coated tablets Each film-coated tablet contains 150 mg capecitabine.
Resultaterne fra en metaanalyse af 14 kliniske studier med data fra mere end 4.700 patienter, som er blevet behandlet med capecitabin, viste at i alle studier kombineret, var kvindeligt køn statistisk signifikant associeret med en øget risiko for udviklingen af hånd- og fodsyndrom og diarré og med en faldende risiko for at udvikle neutropeni.
The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, female gender was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.
Antikoagulantia af coumarintypen
Coumarin-derivative anticoagulation.
En metaanalyse af 14 kliniske studier med data fra mere end 4.700 patienter, som er blevet behandlet med capecitabin, viste i alle studier kombineret at følgende kovarianter var statistisk signifikant associeret med en øget risiko for udviklingen af diarré: stigende capecitabin-startdosis (gram), længere behandlingsvarighed (uger), stigende alder (ved 10-års forøgelse) samt kvindeligt køn.
The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, the following covariates were statistically significantly associated with an increased risk of developing diarrhoea: increasing capecitabine starting dose (gram), increasing duration of study treatment (weeks), increasing age (by 10 year increments), and female gender.
Hydronefrose, Urininkontinens, Hæmaturi, Nokturi, Forøget blodkreatinin
Hydronephrosis, Urinary incontinence, Haematuria, Nocturia, Blood creatinine increased
Ældre patienter ((≥ 65 år) havde, sammenlignet med yngre patienter, flere bivirkninger af grad 3 og 4, inklusiv dem, som førte til seponering, når capecitabin blev anvendt i kombination med andre lægemidler.
When capecitabine was used in combination with other medicinal products, elderly patients (≥65 years) experienced more grade 3 and grade 4 adverse drug reactions, including those leading to discontinuation, compared to younger patients.
I den samlede randomiseringspopulation blev capecitabin vist at være bedre end 5-FU/LV mht. sygdomsfri overlevelse (hazard ratio 0,849; 95 % konfidensinterval 0,739 - 0,976; p = 0,0212) og mht. samlet overlevelse (hazard ratio 0,828; 95 % konfidensinterval 0,705 - 0,971; p = 0,0203).
In the allrandomised population, capecitabine was shown to be superior to 5FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).
Ecansya forårsage svimmelhed, kvalme og træthed.
Ecansya may make you feel dizzy, nauseous or tired.
Ecansya 150 mg filmovertrukne tabletter Ecansya 300 mg filmovertrukne tabletter Ecansya 500 mg filmovertrukne tabletter capecitabin
Ecansya 150 mg film-coated tablets Ecansya 300 mg film-coated tablets Ecansya 500 mg film-coated tablets capecitabine
5.1) til behandling af patienter med lokal fremskreden eller metastatisk brystkræft efter svigt af cytotoksisk kemoterapi.
- in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
1.000 mg/m2 oral 2 gange daglig
Capecitabine 1000 mg/m 2 oral twice daily
Brivudin må derfor ikke administreres samtidig med capecitabin (se pkt.
Therefore, brivudine must not be administered concomitantly with capecitabine (see section 4.3 and 4.4).
Grad 1 hånd- og fodsyndrom defineres som følelsesløshed, dysæstesi/paræstesi, prikken, hævelse eller erytem uden smerter af hænderne og/eller fødderne og/eller ubehag der ikke påvirker patienternes daglige aktiviteter.
Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient's normal activities.
Derfor skal du altid kontakte lægen så snart du får en bivirkning.
These side effects can become severe; therefore, it is important that you always contact your doctor immediately when you start to experience a side effect.
For capecitabindosis på 1.250 mg/m to gange dagligt på dagene 1 til 14 hver 3. uge blev der observeret hånd- og fodsyndrom i alle grader med en hyppighed på 53 % til 60 % i cabecitabinmonoterapistudierne (bestående af studier i adjuverende behandling af kolonkræft, behandling af metastatisk kolorektalkræft og behandling af brystkræft).
Hand-foot syndrome (see section 4.4): For the capecitabine dose of 1250 mg/m2 twice daily on days 1 to 14 every 3 weeks, a frequency of 53% to 60% of all-grades HFS was observed in capecitabine monotherapy trials (comprising studies in adjuvant therapy in colon cancer, treatment of metastatic colorectal cancer, and treatment of breast cancer) and a frequency of 63% was observed in the capecitabine/docetaxel arm for the treatment of metastatic breast cancer.
Monoterapi med capecitabin ved metastatisk kolorektalkræft Data fra to identisk designede, randomiserede, kontrollerede, kliniske multicenterstudier i fase III (SO14695; SO14796) støtter anvendelsen af capecitabin til 1. linjebehandling af metastatisk kolorektalkræft.
Monotherapy with capecitabine in metastatic colorectal cancer Data from two identically-designed, multicentre, randomised, controlled phase III clinical trials (SO14695; SO14796) support the use of capecitabine for first line treatment of metastatic colorectal cancer.
Der er ikke gennemført formelle lægemiddelinteraktionsstudier med capecitabin og andre CYP2C9substrater bortset fra warfarin.
Cytochrome P-450 2C9 substrates: Other than warfarin, no formal interaction studies between capecitabine and other CYP2C9 substrates have been conducted.
Data fra et randomiseret, kontrolleret, klinisk fase III-multicenterstudie hos patienter med kolonkræft i stadium III (Dukes' stadium C) støtter anvendelsen af capecitabin i kombination med oxaliplatin (XELOX) til adjuverende behandling af patienter med kolonkræft (studie NO16968).
Data from one multicentre, randomised, controlled phase 3 clinical trial in patients with stage III (Dukes' C) colon cancer supports the use of capecitabine in combination with oxaliplatin (XELOX) for the adjuvant treatment of patients with colon cancer (NO16968 study).
Bivirkningerne er anført i frekvensgruppering ud fra den højeste hyppighed set i en af de store kliniske studier.
ADRs are added according to the highest incidence seen in any of the major combination trials.
Hyperhidrose, Erytematøst udslæt, Urticaria, Nattesved
Alopecia, Nail disorder Hyperhidrosis, Rash erythematous, Urticaria, Night sweats
Vandfri lactose Croscarmellosenatrium Hypromellose (E-5) Mikrokrystallinsk cellulose Magnesiumstearat
Anhydrous lactose Microcrystalline cellulose (E460) Croscarmellose sodium Hypromellose (E-5) Magnesium stearate
Adjuverende monoterapi med capecitabin ved kolonkræft Data fra et randomiseret, kontrolleret, klinisk fase III-multicenterstudie hos patienter med kolonkræft i stadium III (Dukes' stadium C) støtter anvendelsen af capecitabin som adjuverende behandling af patienter med kolonkræft (XACT-Studie; M66001).
Monotherapy with capecitabine in adjuvant colon cancer Data from one multicentre, randomised, controlled phase III clinical trial in patients with stage III (Dukes' C) colon cancer supports the use of capecitabine for the adjuvant treatment of patients with colon cancer (XACT Study; M66001).
Kombinationsterapi i 1. linjebehandling af metastatisk kolorektalkræft Data fra et multicenter, randomiseret, kontrolleret klinisk fase III-studie (NO16966) understøtter anvendelsen af capecitabin i kombination med oxaliplatin eller i kombination med oxaliplatin og bevacizumab til 1. linjebehandling af metastatisk kolorektalkræft.
Combination therapy in first-line treatment of metastatic colorectal cancer Data from a multicentre, randomised, controlled phase III clinical study (NO16966) support the use of capecitabine in combination with oxaliplatin or in combination with oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
For henholdsvis FOLFIRI plus bevacizumab og XELIRI plus bevacizumab var den mediane progressionfri overlevelse 10,0 og 8,9 måneder; p = 0,64, samlet overlevelse var 25,7 og 27,5 måneder; p = 0,55, og responsrater 45,5 % og 39,8 %; = 0,32.
Median progression-free survival (PFS) was 10.0 and 8.9 months; p=0.64, overall survival 25.7 and 27.5 months; p=0.55 and response rates 45.5 and 39.8%; p=0.32 for FOLFIRI-Bev and XELIRI-Bev, respectively.
Urinvejs-infektion, Cellulitis, Tonsillitis, Faryngitis, Oral candidiasis, Influenza, Gastroenteritis, Svampeinfektion, Infektion, Tandbyld
Pharyngitis, Oral candidiasis, Influenza, Gastroenteritis, Fungal infection, Infection, Tooth abscess
I testene hos den samlede randomiseringspopulation for forskel mellem capecitabin og 5-FU/LV mht. sygdomsfri og samlet overlevelse var hazard ratios hhv. 0,88 (95 % konfidensinterval 0,77 - 1,01; p = 0,068) og 0,86 (95 % konfidensinterval 0,74 - 1,01; p = 0,060).
In the all-randomised population, tests for difference of capecitabine vs 5-FU/LV in disease-free and overall survival showed hazard ratios of 0.88 (95% CI 0.77 - 1.01; p = 0.068) and 0.86 (95% CI 0.74 - 1.01; p = 0.060), respectively.
I studierne blev 603 patienter randomiserede til behandling med capecitabin (1.250 mg/m2 to gange dagligt i 2 uger, efterfulgt af en uges pause, og givet som 3-ugers serier).
In these trials, 603 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles).
Ødem i underekstremiteter, Hypertension, Embolisme og tromboser
Lower limb oedema, Hypertension, Embolism and thrombosis
Resultaterne fra en metaanalyse af 14 kliniske studier med data fra mere end 4.700 patienter, som er blevet behandlet med capecitabin, viste at i alle studier kombineret, var stigende alder (ved 10-års forøgelse) statistisk signifikant associeret med en øget risiko for udviklingen af hånd- og fodsyndrom og diarré og med en faldende risiko for at udvikle neutropeni.
The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, increasing age (by 10 year increments) was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.
(også i munden), influenza, maveinfluenza, tandbylder - knuder under huden (lipom) - fald i blodtal, inklusive blodplader, fortyndet blod (kan ses i blodprøve) - allergi - sukkersyge, nedsat indhold af kalium i blodet, underernæring, øget niveau af triglycerider i blodet - forvirring, panikanfald, depression, nedsat sexlyst, - talebesvær, dårlig hukommelse, koordinationsforstyrrelser, balanceforstyrrelser, besvimelse,
fungal infections (including those of the mouth), influenza, gastroenteritis, tooth abscess - lumps under the skin (lipoma) - decreases in blood cells including platelets, thinning of blood (seen in tests) - allergy - diabetes, decrease in blood potassium, malnutrition, increased blood triglycerides - confusional state, panic attacks, depressed mood, decreased libido - difficulty speaking, impaired memory, loss of movement coordination, balance disorder,
Fremstiller:
Manufacturer
PVC/PVdC/aluminium-blistere: Må ikke opbevares ved temperaturer over 30 °C.
PVC/PVdC/aluminium blisters Do not store above 30°C.
Tabel 5 viser de bivirkninger, der er forbundet med anvendelsen af capecitabin administreret i kombination med forskellige kemoterapiregimer indenfor flere indikationer.
Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3000 patients.
Hypokaliæmi, Hyponatriæmi, Hypomagnesiæmi, Hypokalcæmi, Hyperglycæmi
Hypokalaemia, Hyponatraemia, Hypomagnesaemia,
Erythem,
Petechiae,
Hvis der forekommer behandlingsrelaterede stigninger af bilirubin > 3,0 x UNL eller af hepatiske aminotransferaser (ALAT og ASAT) > 2,5 x UNL skal behandlingen med capecitabin straks afbrydes.
Administration of capecitabine should be interrupted if treatment-related elevations in bilirubin of >3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of >2.5 x ULN occur.
I enkelte tilfælde er der, under samtidig behandling med capecitabin og phenytoin, rapporteret om stigninger i plasmakoncentrationerne af phenytoin, som har medført symptomer på fenytoinintoksikation.
Phenytoin: increased phenytoin plasma concentrations resulting in symptoms of phenytoin intoxication in single cases have been reported during concomitant use of capecitabine with phenytoin.
Den anbefalede initialdosis ved capecitabin-monoterapi, til adjuverende behandling af kolonkræft, til behandling af metastatisk kolorektalkræft eller af lokalt fremskreden eller metastatisk brystkræft er 1.250 mg/m2 administreret to gange dagligt (morgen og aften, svarende til en daglig dosis på 2.500 mg/m2) i 14 dage, efterfulgt af 7 dages pause.
Given as monotherapy, the recommended starting dose for capecitabine in the adjuvant treatment of colon cancer, in the treatment of metastatic colorectal cancer or of locally advanced or metastatic breast cancer is 1250 mg/m2 administered twice daily (morning and evening; equivalent to
Patienter bør monitoreres omhyggeligt for oftalmologiske komplikationer såsom keratitis og sygdomme på cornea.
Ophthalmologic complications: Patients should be carefully monitored for ophthalmological complications such as keratitis and corneal disorders, especially if they have a prior history of eye disorders.
I dette studie blev 1.987 patienter randomiseret til behandling med capecitabin (1.250 mg/m2 to gange dagligt i 2 uger, efterfulgt af en uges pause, givet som 3-ugers serier i 24 uger) eller til behandling med 5-FU og leucovorin (Mayo Clinic-regime: 20 mg/m2 leucovorin intravenøs, efterfulgt af 425 mg/m2 intravenøs 5-FU som bolus på dag 1 til 5, hver 28. dag i 24 uger).
In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m2 leucovorin intravenous followed by 425 mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks).
I disse studier blev 236 patienter behandlet med capecitabin (1.250 mg/m2 to gange dagligt i 2 uger efterfulgt af en uges pause).
In these trials, a total of 236 patients were treated with capecitabine (1250 mg/m2 twice daily for 2 weeks followed by 1-week rest period).
I den egnede patientpopulation og intent-to-treat-populationen blev der demonstreret non-inferioritet af XELOX-armen, sammenlignet med FOLFOX-4-armen, med hensyn til progressionsfri overlevelse (se tabel 7).
Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival in the eligible patient population and the intent-to-treat population (see table 7).
Sammenlignet med hele populationen er hyppigheden af bivirkninger af grad 3 eller 4 forøget hos patienter med moderat nyreinsufficiens (creatininclearance 30-50 ml/min) (se pkt.
The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).
INFORMATION I BRAILLE-SKRIFT Ecansya 300 mg
INFORMATION IN BRAILLE Ecansya 300 mg
Sådan skal du tage Ecansya
How to take Ecansya
Kæbesmerter, Muskelspasmer, Trismus, Muskelsvaghed
Pain in jaw, Muscle spasms, Trismus, Muscular weakness
Tabletovertrækket - Ecansya 150 mg filmovertrukne tabletter Hypromellose (6cps)
Tablet coating - Ecansya 150 mg film-coated tablets Hypromellose (6cps)
• Grad 2 ved 1. forekomst
• Grade 2 -1st appearance
Diabetes, Hypokaliæmi, Appetitforstyrrelser, Underernæring, Hypertriglyceridæmi
Hypokalaemia, Appetite disorder, Malnutrition, Hypertriglyceridaemia
Atrieflimren, Iskæmisk hjertesygdom/infarkt
Atrial fibrillation, Cardiac ischaemia/infarction
Livstruende toksicitet, der manifesterer sig som akut overdosis, kan forekomme hos patienter med uopdaget DPD-mangel ved behandling med capecitabin samt hos de patienter, der testes negative for specifikke DPYD-variationer (se pkt.
In patients with unrecognised DPD deficiency treated with capecitabine as well as in those patients who test negative for specific DPYD variations, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9).
Stenosis canaliculus lacrimalis (sjælden), Hornhindesygdom (sjælden), Keratitis (sjælden), Punktat keratitis (sjælden)
Lacrimal duct stenosis (rare), Corneal disorders(rare), keratitis (rare), punctate keratitis (rare)
12,1 måneder p = 0,30
P=0.30
Hos aber blev der set abort og embryoletalitet efter høje doser, men der var ikke tegn på teratogenicitet.
In monkeys, abortion and embryolethality were observed at high doses,
Parameter: Progressionsfri overlevelse EPP ITT
Parameter: Progression-free Survival PPP
Fotosensitivitetsreaktioner, Palmart erythem, Hævelse i ansigtet, Purpura, Recall fænomen ved strålebehandling
Blister, Skin ulcer, Rash, Urticaria, Photosensitivity reaction, Palmar erythema, Swelling face, Purpura, Radiation recall syndrome
Der er ikke tilstrækkelige data til at anbefale en bestemt dosis til patienter med delvis DPD-aktivitet, målt ved en specifik test. Der er rapporteret at DPYD*2A, c.1679T>G varianter førte til en større reduction i enzymaktivitet end andre varianter, med en højere forekomst af bivirkninger til følge.
It has been reported that the DPYD*2A, c.1679T>G variants lead to a greater reduction in enzymatic activity than the other variants with a higher risk of side effects.
Ansigtsrødme, Hypotension, Hypertensiv krise, Hedetur, Flebitis
Flushing, Hypotension, Hypertensive crisis, Hot flush, Phlebitis
Eksponering for delte eller knuste capecitabin-tabletter Skulle eksponering for delte eller knuste capecitabin-tabletter hænde, er følgende bivirkninger observeret: øjenirritation, hævelse af øjnene, hududslæt, hovedpine, parestæsi, diarré, kvalme, maveirritaiton samt opkast.
In the instance of exposure to crushed or cut capecitabine tablets, the following adverse drug reactions have been reported: eye irritation, eye swelling, skin rash, headache, paresthesia, diarrhea, nausea, gastric irritation, and vomiting.
INFORMATION I BRAILLE-SKRIFT Ecansya 150 mg
INFORMATION IN BRAILLE Ecansya 150 mg
INFORMATION I BRAILLE-SKRIFT Ecansya 500 mg
INFORMATION IN BRAILLE Ecansya 500 mg
Ecansya 500 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 500 mg capecitabin.
Ecansya 500 mg film-coated tablets Each film-coated tablet contains 500 mg capecitabine.
Pyreksi, Svaghed, Letargi,
Pyrexia, Weakness, Lethargy, Temperature intolerance
Ecansya 300 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 300 mg capecitabin.
Ecansya 300 mg film-coated tablets Each film-coated tablet contains 300 mg capecitabine.
Diarré (se pkt.
Diarrhoea (see section 4.4):
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Bivirkningerne er baseret på en samlet analyse af kliniske sikkerhedsdata fra 7 kliniske studier med 949 patienter (2 fase III- og 5 fase II-kliniske studier i metastatisk kolorektalkræft og metastatisk brystkræft) og omfatter: kardiomyopati, hjerteinsufficiens, dødsfald og ventrikulære ekstrasystoler.
In addition to the ADRs described in tables 4 and 5, the following ADRs with an incidence of less than 0.1% were associated with the use of capecitabine monotherapy based on a pooled analysis from clinical safety data from 7 clinical trials including 949 patients (2 phase III and 5 phase II clinical trials in metastatic colorectal cancer and metastatic breast cancer): cardiomyopathy, cardiac failure, sudden death, and ventricular extrasystoles.
- Ecansya 300 mg filmovertrukne tabletter Hypromellose (6cps)
- Ecansya 300 mg film-coated tablets Hypromellose (6cps)
I EORTC-studiet blev patienterne randomiseret til ublindet at få enten FOLFIRI (n=41) eller XELIRI (n=44).
In the EORTC study patients were randomised to receive either open label FOLFIRI (n=41) or XELIRI (n=44) with additional randomisation to either double-blind treatment with celecoxib or placebo.
- Øvrige indholdsstoffer (hjælpestoffer): Tabletkernen Vandfri lactose, croscarmellosenatrium, hypromellose (E-5), mikrokrystallinsk cellulose,
Anhydrous lactose, croscarmellose sodium, hypromellose (E-5), microcrystalline cellulose, magnesium stearate.
• Grad 4 ved 1. forekomst
• Grade 4 -1st appearance
Kombinationsterapi i 2. linjebehandling af metastatisk kolorektalkræft Data fra et multicenter, randomiseret, kontrolleret klinisk fase III-studie (NO16967) understøtter anvendelsen af capecitabin i kombination med oxaliplatin til 2. linjebehandling af metastatisk kolorektalkræft.
Combination therapy in second-line treatment of metastatic colorectal cancer Data from a multicentre, randomised, controlled phase III clinical study (NO16967) support the use of capecitabine in combination with oxaliplatin for the second-line treatment of metastastic colorectal cancer.